Загрузка...
Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country–Nepal: Cost, Efficacy, and Safety
Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered, mutant tissue plasminogen activator, is an alternative thrombolytic agent. The economic feasibility of stroke treatment has been a matter of huge debate and discussion thus far. Th...
Сохранить в:
| Опубликовано в: : | Cureus |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Cureus
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5890961/ https://ncbi.nlm.nih.gov/pubmed/29651371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.2178 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|